Our Studies
Our Clinical Research Studies
Dedicated to Clinical Research Full Time.
BioSolutions Open Protocol Summaries
INDICATION
AGE CRITERIA
DESCRIPTION
COPD
40-80
A Randomized, Double-blind, Parallel Group, Multi-center, Phase III Study to Assess the Efficacyof Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS)
BioSolutions Start Up (Upcoming) Protocol Summaries
INDICATION
AGE CRITERIA
DESCRIPTION
Systemic Inflammatory Rheumatic Disease
≥18 Yr old
Phase II, Double Blind, Placebo Controlled, Randomized Study Examining Natrunix in Combination with Standard of Care in HLA-B27 Positive Subjects with Axial Spondyloarthritis
Lupus
18 to 75
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy
Asthma
18 to 80
A Phase 2b, Randomised, Double-Blind, Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 Given Once Daily and Administered via the Saphira Device for 12-52 Weeks in Adults with Uncontrolled Moderate to Severe Asthma (LEVENT)
RA
18 to 81
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Abiprubart in Participants with Sjögren’s Disease
Thank You
Our Sponsors
Thank You Sponsors of Creativity & Innovation.
Partners
Our Network
